References
- Barajas RF Jr, Rubenstein JL, Chang JS, . Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol 2010;31:60–66.
- Baehring JM, Damek D, Martin EC, . Neurolymphomatosis. Neuro Oncol 2003;5:104–115.
- Levitt LJ, Dawson DM, Rosenthal DS, . CNS involvement in the non-Hodgkin's lymphomas. Cancer 1980;45:545–552.
- Herrlinger U, Glantz M, Schlegel U, . Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more. Semin Oncol 2009;36:S25–S34.
- Phuphanich S, Maria B, Braeckman R, . A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol 2007;81:201–208.
- Mascalchi M, Filippi M, Floris R, . Diffusion-weighted MR of the brain: methodology and clinical application. Radiol Med 2005;109:155–197.
- Geller HM, Cheng KY, Goldsmith NK, . Oxidative stress mediates neuronal DNA damage and apoptosis in response to cytosine arabinoside. J Neurochem 2001;78:265–275.
- Lai R, Abrey LE, Rosenblum MK, . Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 2004;62:451–456.
- DeAngelis LM, Posner JB. Neurological complications of cancer. 2nd ed. New York: Oxford University Press; 2009.
- Jabbour E, O'Brien S, Kantarjian H, . Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007;109:3214–3218.
- Jaeckle KA, Batchelor T, O'Day SJ, . An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 2002;57:231–239.
- Glantz MJ, LaFollette S, Jaeckle KA, . Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999;17:3110–3116.
- Benesch M, Sovinz P, Krammer B, . Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. J Pediatr Hematol Oncol 2007;29: 222–226.
- Bomgaars L, Geyer JR, Franklin J, . Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol 2004;22:3916–3921.
- Glantz MJ, Jaeckle KA, Chamberlain MC, . A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999;5:3394–3402.